Biomm S.A Cash Flow Conversion Efficiency
Biomm S.A cash flow conversion efficiency. Based on the latest financial reports, Biomm S.A (BIOM3) has a cash flow conversion efficiency ratio of -0.164x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$-46.72 Million ≈ $-9.17 Million USD) by net assets (R$284.10 Million ≈ $55.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biomm S.A (2006–2024)
Cash flow conversion efficiency of Biomm S.A from 2006 to 2024. This chart illustrates how Biomm S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Biomm S.A (BIOM3) share price today for real-time trading data and today's change.
Biomm S.A Cash Flow Conversion Ratio Explained
Biomm S.A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biomm S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomm S.A ranked by their cash flow conversion efficiency. Also see Biomm S.A (BIOM3) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bioversys AG
SW:BIOV
|
N/A |
|
Karsan Otomotiv Sanayi ve Ticaret AS
IS:KARSN
|
0.313x |
|
Nordic Halibut AS
OL:NOHAL
|
0.009x |
|
Gia Lai Electricity JSC
VN:GEG
|
0.076x |
|
SANIONA AB (PUBL)
F:30S
|
-0.121x |
|
LaFayette Acquisition Corp. Ordinary Share
NASDAQ:LAFA
|
-0.002x |
|
LongDa Construction & Development Corp
TW:5519
|
-0.025x |
|
Cti Logistics Ltd
AU:CLX
|
0.142x |
Annual Cash Flow Conversion Efficiency for Biomm S.A (2006–2024)
The table below shows the annual cash flow conversion efficiency of Biomm S.A from 2006 to 2024. Review Biomm S.A free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | R$262.78 Million ≈ $51.56 Million |
R$-91.84 Million ≈ $-18.02 Million |
-0.350x | +42.54% |
| 2023-12-31 | R$122.94 Million ≈ $24.12 Million |
R$-74.78 Million ≈ $-14.67 Million |
-0.608x | -53.63% |
| 2022-12-31 | R$159.11 Million ≈ $31.22 Million |
R$-63.00 Million ≈ $-12.36 Million |
-0.396x | +52.89% |
| 2021-12-31 | R$111.59 Million ≈ $21.90 Million |
R$-93.78 Million ≈ $-18.40 Million |
-0.840x | -66.12% |
| 2020-12-31 | R$191.48 Million ≈ $37.57 Million |
R$-96.87 Million ≈ $-19.01 Million |
-0.506x | -0.11% |
| 2019-12-31 | R$153.56 Million ≈ $30.13 Million |
R$-77.61 Million ≈ $-15.23 Million |
-0.505x | -21.54% |
| 2018-12-31 | R$106.09 Million ≈ $20.82 Million |
R$-44.12 Million ≈ $-8.66 Million |
-0.416x | +54.67% |
| 2017-12-31 | R$59.30 Million ≈ $11.64 Million |
R$-54.41 Million ≈ $-10.68 Million |
-0.917x | -58.00% |
| 2016-12-31 | R$65.93 Million ≈ $12.94 Million |
R$-38.28 Million ≈ $-7.51 Million |
-0.581x | -380.95% |
| 2015-12-31 | R$115.13 Million ≈ $22.59 Million |
R$-13.90 Million ≈ $-2.73 Million |
-0.121x | +34.64% |
| 2014-12-31 | R$107.10 Million ≈ $21.02 Million |
R$-19.78 Million ≈ $-3.88 Million |
-0.185x | -91.50% |
| 2013-12-31 | R$108.94 Million ≈ $21.38 Million |
R$-10.51 Million ≈ $-2.06 Million |
-0.096x | -129.36% |
| 2012-12-31 | R$-22.00 Million ≈ $-4.32 Million |
R$-7.23 Million ≈ $-1.42 Million |
0.329x | +61.48% |
| 2011-12-31 | R$-8.76 Million ≈ $-1.72 Million |
R$-1.78 Million ≈ $-349.66K |
0.203x | -82.19% |
| 2010-12-31 | R$-4.06 Million ≈ $-796.84K |
R$-4.64 Million ≈ $-910.45K |
1.143x | -99.77% |
| 2009-12-31 | R$-15.00K ≈ $-2.94K |
R$-7.50 Million ≈ $-1.47 Million |
499.733x | +106719.64% |
| 2008-12-31 | R$-12.22 Million ≈ $-2.40 Million |
R$-5.71 Million ≈ $-1.12 Million |
0.468x | -30.15% |
| 2006-12-31 | R$3.09 Million ≈ $606.12K |
R$2.07 Million ≈ $405.98K |
0.670x | -- |
About Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more